From: Boris Nikolic •t: Ina> To: "Jeffrey Epstein ([email protected])" <[email protected]> Subject: draft for a fund Date: Tue, 22 Oct 2013 00:13:56 +0000 This is a draft that I sent to Yuri on Friday. Please let's discuss. Life Sciences & Technology ("LST") Fund With a target size of [$250 - $400 million] of committed capital, the LST Fund intends to invest at the intersection of life science and digital technology. Recent advances in molecular medicine, electronic sensor technology and communication platforms create the opportunity to dramatically reduce inefficiencies in the diagnosis, treatment and delivery of healthcare. Similar to other industries, the life sciences and healthcare sectors could be transformed by disruptive business models that change the way consumers — otherwise known as patients — interact with health care. In an environment of health care reform requiring quality, affordable care, the LST Fund will invest in companies with transformative technologies and business models that create financial value either through making healthcare more efficient and/or serving consumers directly. The LST Fund's portfolio is expected to comprise approximately [20-25] companies with an average of [$10-15 million] invested per company. The investment period of the LST Fund will be [4-5] years with a 10 year fund life. The General Partners are Yuri Milner and Boris Nikolic. The General Partners intend to invest a significant portion [10-20%) of the capital of the LST Fund. The management fee is 2% and a carried interest is 20% of net gain. Preferred Limited partners will be selected strategic individuals. The LST Fund will be based in San Francisco, and co-locate with DST Global in order to take advantage of the back office capabilities of DST. The LST Fund intends to be an investor in disruptive business models and will therefore be disciplined about investing only in the highest quality entrepreneurs with an unfair advantage in a